Glenmark Pharmaceuticals Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 23.6%)
- Efficient capital deployment (ROCE 39.8%)
- Attractively valued vs sector (P/E 19.6x vs industry 50.2x)
- Virtually debt-free
Concerns
Today's Price Action
The stock closed at ₹2300 with no price change from the previous session, indicating a flat intra‑day close despite the‑day's normal market activity. Trading volume registered exactly 4,55,748 shares, which is identical to the 20‑day average volume, suggesting that buyer‑seller participation remains steady and there is no unusual accumulation or distribution pressure.
Valuation Snapshot
The trailing price‑to‑earnings multiple stands at 19.6, while a sector‑wide comparative P/E figure is not disclosed, so a direct relative valuation cannot be quantified at this time. A price‑to‑book ratio of zero together with an impressive return on equity of 23.6 % reflects strong profitability relative to the book value of shareholders’ capital.
Key Levels to Watch
The 52‑week price band ranges from a low of ₹1793 to a high of ₹2538; the current level of ₹2300 sits roughly 37 % above the year‑low and about 9 % beneath the year‑high, positioning the share in the upper half of its annual range. Because open‑interest figures for the nearest futures contracts are unavailable, concrete support or resistance zones derived from derivatives positioning cannot be highlighted.
Chart Pattern
On the daily timeframe, a bullish Marubozu candle and a Bullish Engulfing pattern appeared three trading sessions ago, each preceded by a hammer formation six sessions earlier; these three consecutive bullish formations collectively signal that recent price action has been dominated by higher close prices and reduced lower‑shadow lengths, a characteristic of short‑term upward momentum. The pattern chronology indicates that sellers have been increasingly unable to push the price below the opening levels during this span.
Data Summary
Key metrics show a flat price at ₹2300, a P/E of 19.6 and an ROE of 23.6 %, while the market capitalisation is reported as ₹0 Cr. Volume remains aligned with the 20‑day average and the price currently resides within the upper portion of its 52‑week range, reflecting a balanced trading environment without pronounced short‑term distortions.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
GLENMARK · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% |
| FII | 23.71% | 21.38% | 20.98% | 23.05% | 23.51% | 23.15% |
| DII | 10.92% | 13.36% | 13.93% | 13.21% | 13.85% | 14.60% |
| Public | 18.70% | 18.58% | 18.42% | 17.06% | 15.96% | 15.56% |
| Govt | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
Corporate Events
To consider and approve the financial results for the period ended September 30, 2026
Dividend - Rs 2.50 Per Share
To consider and approve the financial results for the period ended Jun 30, 2026
To consider and approve the financial results for the period ended March 31, 2026 and dividend
Interim Dividend - Rs 2.50 Per Share
Dividend - Rs 2.50 Per Share
Dividend - Rs 2.50 Per Share
Dividend - Rs 2.50 Per Share
Latest News
All newsGlenmark receives credit rating update
*Glenmark receives credit rating update.* The company's latest credit rating has been disclosed in a regulatory filing. No adverse changes reported; outlook remains stable. **Rating agencies** reaffirm company’s financial health. 📊 *STOCKS:* $GLENMARK | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CreditRating
Indian firm wins FDA approval for superbug antibiotic
*Indian firm wins FDA approval for superbug antibiotic* — Glenmark Pharmaceuticals receives US FDA nod for its novel antibiotic, marking a breakthrough in treating drug-resistant infections. The approved drug targets serious bacterial infections with limited treatment options. This paves the way for US market entry and potential revenue growth. Approval underscores India’s rising role in global pharma innovation. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #FDA
Glenmark's Goa plant gets FDA VAI classification
*Glenmark's Goa facility receives VAI classification in FDA inspection.* The U.S. FDA issued a VAI (Voluntary Action Indicated) status in the Establishment Inspection Report, signaling minor observations. This indicates the facility is largely compliant but may require corrective actions. No product recalls or major compliance failures were reported. 📊 *STOCKS:* $GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDA
Glenmark launches RYALTRIS® in Brazil for respiratory treatment
*Glenmark launches RYALTRIS® in Brazil for respiratory treatment.* The launch marks Glenmark's expanded footprint in the global respiratory market. RYALTRIS® is a combination therapy for asthma and COPD. This strategic move strengthens its presence in Latin America. 📊 *STOCKS:* $GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Launch
Glenmark Pharma launches Calcium Gluconate Injection in USA
*Glenmark Pharma launches Calcium Gluconate Injection in USA.* The product is approved by the USFDA and targets the injectable generics market. Launch includes **three dosage forms** — 1,000 mg/10 mL, 5,000 mg/50 mL, and 10,000 mg/100 mL. This strengthens Glenmark’s presence in the **US hospital generics segment**. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Glenmark gets U.S. FDA nod for nasal spray.
*Glenmark gets U.S. FDA nod for nasal spray.* Glenmark Pharmaceuticals has received U.S. FDA approval for its generic Fluticasone Propionate Nasal Spray, **0.05 mg (50 mcg)/spray**, a widely used corticosteroid for allergic rhinitis. This approval allows Glenmark to launch the product in the U.S., expanding its respiratory portfolio. The U.S. market for this drug was valued at **over $200 million** annually, offering significant revenue potential. 📊 *STOCKS:* $GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDAApproval
Glenmark launches Olanzapine for Injection in USA
*Glenmark launches Olanzapine for Injection in USA* — Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection, **10 mg/vial**, a single-dose vial. The product is indicated for schizophrenia and bipolar disorder. This launch expands Glenmark’s presence in the U.S. generics market. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ProductLaunch
Glenmark advances Phase 3 trial for ovarian cancer drug
*Glenmark advances Phase 3 trial for ovarian cancer drug*. The company has progressed its multi-country Phase 3 clinical trial of Trastuzumab rezetecan in platinum-resistant ovarian cancer. This advancement signals positive momentum in its oncology pipeline. **Phase 3 trials** are pivotal for regulatory approval and market potential. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ClinicalTrial
Glenmark Pharma launches Methylene Blue injection in USA
Glenmark Pharmaceuticals launched Methylene Blue Injection USP, 50 mg/10 mL in the US market. The product is indicated for the treatment of acquired methemoglobinemia. Launch expands Glenmark’s presence in the US generics segment. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Launch
Glenmark launches acne drug Winlevi in Europe
*Glenmark launches acne drug Winlevi in Europe* — Glenmark Pharmaceuticals has launched Winlevi® (clascoterone) 10 mg/g cream in key European markets for acne vulgaris. The product launch expands its dermatology portfolio in Europe. Winlevi is a first-in-class topical androgen receptor inhibitor. This move strengthens Glenmark’s presence in the European skincare market. 📊 *STOCKS:* GLENMARK | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #DrugLaunch
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3.9K Cr 35.5% | ₹6.0K Cr 85.3% | ₹3.3K Cr 0.2% | ₹3.3K Cr 3.9% | ₹3.4K Cr 1.3% | ₹3.4K Cr 5.9% | ₹3.2K Cr 5.9% | ₹3.1K Cr |
| Op. Profit | ₹870 Cr 63.1% | ₹2.4K Cr 306.2% | ₹581 Cr 3.6% | ₹561 Cr 6.5% | ₹600 Cr 0.3% | ₹602 Cr 2.4% | ₹588 Cr 16.7% | ₹504 Cr |
| OPM | 22.0% 43.6% | 39.0% 116.7% | 18.0% 5.9% | 17.0% 5.6% | 18.0% 0.0% | 18.0% 0.0% | 18.0% 12.5% | 16.0% |
| Net Profit | ₹403 Cr 33.9% | ₹610 Cr 1197.9% | ₹47 Cr 1075.0% | ₹4 Cr 98.9% | ₹348 Cr 1.7% | ₹354 Cr 4.1% | ₹340 Cr 128.0% | ₹-1.2K Cr |
| EPS (₹) | 14.29 33.9% | 21.63 1203.0% | 1.66 937.5% | 0.16 98.7% | 12.33 1.8% | 12.55 4.1% | 12.06 127.9% | -43.17 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹17.0K Cr 27.5% | ₹13.3K Cr 12.8% | ₹11.8K Cr 2.0% | ₹11.6K Cr 5.9% | ₹12.3K Cr 12.4% | ₹10.9K Cr 2.8% | ₹10.6K Cr 7.9% | ₹9.9K Cr 8.7% | ₹9.1K Cr 0.1% | ₹9.1K Cr |
| Expenses | ₹12.4K Cr 13.1% | ₹11.0K Cr 3.3% | ₹10.6K Cr 6.7% | ₹9.9K Cr 0.3% | ₹10.0K Cr 12.6% | ₹8.9K Cr 0.9% | ₹8.9K Cr 8.0% | ₹8.3K Cr 11.0% | ₹7.5K Cr 5.9% | ₹7.0K Cr |
| Op. Profit | ₹4.6K Cr 94.5% | ₹2.4K Cr 96.7% | ₹1.2K Cr 26.9% | ₹1.6K Cr 29.7% | ₹2.3K Cr 11.7% | ₹2.1K Cr 22.7% | ₹1.7K Cr 7.1% | ₹1.6K Cr 1.9% | ₹1.6K Cr 20.6% | ₹2.0K Cr |
| OPM | 27.0% 50.0% | 18.0% 80.0% | 10.0% 28.6% | 14.0% 26.3% | 19.0% 0.0% | 19.0% 18.8% | 16.0% 0.0% | 16.0% 11.1% | 18.0% 18.2% | 22.0% |
| Other Income | ₹-1.8K Cr 596.9% | ₹-259 Cr 177.1% | ₹336 Cr 3460.0% | ₹-10 Cr 90.1% | ₹-101 Cr 206.3% | ₹95 Cr 50.3% | ₹191 Cr 49.1% | ₹375 Cr 321.3% | ₹89 Cr 302.3% | ₹-44 Cr |
| Interest | ₹209 Cr 1.0% | ₹207 Cr 59.9% | ₹516 Cr 47.9% | ₹349 Cr 17.1% | ₹298 Cr 15.6% | ₹353 Cr 6.4% | ₹377 Cr 12.5% | ₹335 Cr 17.1% | ₹286 Cr 20.7% | ₹237 Cr |
| Depreciation | ₹573 Cr 17.9% | ₹486 Cr 16.5% | ₹582 Cr 2.3% | ₹569 Cr 16.8% | ₹487 Cr 9.7% | ₹444 Cr 6.5% | ₹417 Cr 27.9% | ₹326 Cr 7.9% | ₹302 Cr 14.4% | ₹264 Cr |
| PBT | ₹2.0K Cr 41.9% | ₹1.4K Cr 222.4% | ₹434 Cr 38.6% | ₹707 Cr 50.9% | ₹1.4K Cr 4.3% | ₹1.4K Cr 26.1% | ₹1.1K Cr 15.8% | ₹1.3K Cr 16.3% | ₹1.1K Cr 24.9% | ₹1.5K Cr |
| Tax % | 31.0% 24.0% | 25.0% 94.2% | 430.0% 814.9% | 47.0% 51.6% | 31.0% 3.3% | 30.0% 3.4% | 29.0% 0.0% | 29.0% 3.6% | 28.0% 7.7% | 26.0% |
| Net Profit | ₹1.4K Cr 30.1% | ₹1.0K Cr 173.0% | ₹-1.4K Cr 480.4% | ₹377 Cr 62.1% | ₹994 Cr 2.5% | ₹970 Cr 25.0% | ₹776 Cr 16.1% | ₹925 Cr 15.0% | ₹804 Cr 27.5% | ₹1.1K Cr |
| EPS (₹) | 48.26 30.0% | 37.11 169.7% | -53.22 605.4% | 10.53 68.4% | 33.37 2.9% | 34.38 25.0% | 27.5 16.1% | 32.78 15.1% | 28.49 27.5% | 39.29 |
| Div Payout | 10.0% 42.9% | 7.0% 240.0% | -5.0% 120.8% | 24.0% 242.9% | 7.0% 0.0% | 7.0% 22.2% | 9.0% 50.0% | 6.0% 14.3% | 7.0% 40.0% | 5.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹28 Cr 0.0% | ₹28 Cr 0.0% | ₹28 Cr 0.0% | ₹28 Cr 0.0% | ₹28 Cr 0.0% | ₹28 Cr 0.0% | ₹28 Cr 0.0% | ₹28 Cr 0.0% | ₹28 Cr 0.0% | ₹28 Cr |
| Reserves | ₹9.6K Cr 8.3% | ₹8.8K Cr 12.8% | ₹7.8K Cr 17.2% | ₹9.4K Cr 4.3% | ₹9.1K Cr 28.7% | ₹7.0K Cr 16.5% | ₹6.0K Cr 8.3% | ₹5.6K Cr 8.6% | ₹5.1K Cr 15.0% | ₹4.5K Cr |
| Borrowings | ₹1.2K Cr 50.5% | ₹2.5K Cr 100.9% | ₹1.2K Cr 73.3% | ₹4.6K Cr 16.3% | ₹4.0K Cr 20.5% | ₹5.0K Cr 2.4% | ₹4.9K Cr 9.4% | ₹4.4K Cr 4.1% | ₹4.6K Cr 1.8% | ₹4.7K Cr |
| Other Liabilities | ₹8.2K Cr 75.5% | ₹4.7K Cr 11.6% | ₹5.3K Cr 0.2% | ₹5.3K Cr 32.1% | ₹4.0K Cr 13.6% | ₹3.5K Cr 5.5% | ₹3.7K Cr 15.3% | ₹3.2K Cr 15.8% | ₹2.8K Cr 9.6% | ₹2.5K Cr |
| Total Liabilities | ₹19.0K Cr 18.8% | ₹16.0K Cr 11.4% | ₹14.4K Cr 25.9% | ₹19.4K Cr 13.6% | ₹17.1K Cr 9.5% | ₹15.6K Cr 6.2% | ₹14.7K Cr 10.4% | ₹13.3K Cr 5.5% | ₹12.6K Cr 7.1% | ₹11.8K Cr |
Assets | ||||||||||
| Fixed Assets | ₹5.2K Cr 16.1% | ₹4.5K Cr 6.6% | ₹4.2K Cr 22.4% | ₹5.4K Cr 7.9% | ₹5.9K Cr 14.8% | ₹5.1K Cr 2.0% | ₹5.0K Cr 37.0% | ₹3.7K Cr 21.1% | ₹3.0K Cr 10.0% | ₹2.8K Cr |
| CWIP | ₹695 Cr 16.8% | ₹835 Cr 26.1% | ₹662 Cr 44.4% | ₹1.2K Cr 17.8% | ₹1.0K Cr 26.9% | ₹1.4K Cr 13.1% | ₹1.2K Cr 12.7% | ₹1.4K Cr 24.7% | ₹1.1K Cr 58.5% | ₹708 Cr |
| Investments | ₹42 Cr 25.0% | ₹56 Cr 92.9% | ₹790 Cr 1655.6% | ₹45 Cr 10.0% | ₹50 Cr 100.0% | ₹25 Cr 0.0% | ₹25 Cr 16.7% | ₹30 Cr 100.0% | ₹15 Cr 6.3% | ₹16 Cr |
| Other Assets | ₹13.1K Cr 23.0% | ₹10.6K Cr 22.0% | ₹8.7K Cr 31.6% | ₹12.7K Cr 25.8% | ₹10.1K Cr 11.8% | ₹9.0K Cr 7.7% | ₹8.4K Cr 2.5% | ₹8.2K Cr 2.8% | ₹8.4K Cr 1.7% | ₹8.3K Cr |
| Total Assets | ₹19.0K Cr 18.8% | ₹16.0K Cr 11.4% | ₹14.4K Cr 25.9% | ₹19.4K Cr 13.6% | ₹17.1K Cr 9.5% | ₹15.6K Cr 6.2% | ₹14.7K Cr 10.4% | ₹13.3K Cr 5.5% | ₹12.6K Cr 7.1% | ₹11.8K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹-828 Cr 212.5% | ₹-265 Cr 142.4% | ₹625 Cr 43.6% | ₹1.1K Cr 1.9% | ₹1.1K Cr 18.8% | ₹1.4K Cr 5.1% | ₹1.3K Cr 19.7% | ₹1.6K Cr 150.8% | ₹657 Cr 90.4% | ₹345 Cr |
| Investing CF | ₹58 Cr 98.7% | ₹4.4K Cr 951.8% | ₹-515 Cr 63.0% | ₹-316 Cr 52.3% | ₹-662 Cr 14.5% | ₹-774 Cr 12.3% | ₹-883 Cr 12.0% | ₹-1.0K Cr 0.2% | ₹-1.0K Cr 5.4% | ₹-950 Cr |
| Financing CF | ₹787 Cr 120.1% | ₹-3.9K Cr 4972.7% | ₹-77 Cr 85.2% | ₹-520 Cr 17.6% | ₹-442 Cr 0.7% | ₹-445 Cr 39.8% | ₹-739 Cr 57.9% | ₹-468 Cr 186.2% | ₹543 Cr 22.3% | ₹699 Cr |
| Net Cash Flow | ₹17 Cr 92.1% | ₹215 Cr 571.9% | ₹32 Cr 88.2% | ₹272 Cr 871.4% | ₹28 Cr 83.9% | ₹174 Cr 158.6% | ₹-297 Cr 267.8% | ₹177 Cr 11.1% | ₹199 Cr 114.0% | ₹93 Cr |
| Free Cash Flow | ₹-1.6K Cr 35.6% | ₹-1.2K Cr 1649.3% | ₹75 Cr 76.6% | ₹320 Cr 29.8% | ₹456 Cr 26.0% | ₹616 Cr 13.5% | ₹712 Cr 13.9% | ₹625 Cr 922.4% | ₹-76 Cr 86.0% | ₹-544 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 92d 61.4% | 57d 50.4% | 115d 25.0% | 92d 7.0% | 86d 3.6% | 83d 2.5% | 81d 13.8% | 94d 3.1% | 97d 19.2% | 120d |
| Inventory Days | 254d 22.1% | 208d 2.5% | 203d 2.4% | 208d 9.6% | 230d 9.0% | 211d 13.5% | 244d 0.0% | 244d 18.4% | 299d 20.1% | 249d |
| Days Payable | 256d 21.9% | 210d 22.1% | 172d 9.5% | 190d 15.9% | 226d 7.6% | 210d 12.9% | 241d 7.1% | 225d 7.4% | 243d 21.1% | 308d |
| Cash Conv. Cycle | 90d 60.7% | 56d 61.9% | 147d 33.6% | 110d 22.2% | 90d 7.1% | 84d 1.2% | 85d 24.8% | 113d 25.7% | 152d 149.2% | 61d |
| Working Capital Days | 44d 2300.0% | -2d 101.4% | 141d 116.9% | 65d 3.0% | 67d 24.1% | 54d 15.6% | 64d 35.4% | 99d 20.8% | 125d 145.1% | 51d |
| ROCE | 19.0% 58.3% | 12.0% 20.0% | 10.0% 37.5% | 16.0% 6.7% | 15.0% 7.1% | 14.0% 6.7% | 15.0% 0.0% | 15.0% 28.6% | 21.0% 10.5% | 19.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]
HealthcarePharmaceuticals & Biotechnology